93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…
NEW YORK, Nov. 14, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…
Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor…
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data…
NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…
A new international study presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology…
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused…
These first-of-kind money market rates transform Aave pool activity into conventional overnight rates to support interest rate derivatives and floating…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…